Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.

被引：6
|
作者：
Mao, Lili
Cao, Yabing
Sheng, Xinan
Bai, Xue
Chi, Zhihong
Cui, Chuanliang
Wang, Xuan
Tang, Bixia
Lian, Bin
Yan, Xieqiao
Li, Siming
Zhou, Li
Wei, Xiaoting
Li, Caili
Qi, Zhong Hui
Si, Lu
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Dept Renal Canc & Melanoma, Collaborat Innovat Ctr Canc Med, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China
[2] Kiang Wu Hosp, Macau, Peoples R China
[3] Peking Univ, Canc Hosp, Beijing, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.9528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9528
引用
收藏
页数：1
相关论文
共 50 条
  • [21] P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
    Li, Paiyun
    Zhang, Xuehong
    Gu, Liankun
    Zhou, Jing
    Deng, Dajun
    PLOS ONE, 2019, 14 (10):
  • [22] p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression
    Piccinin, S
    Doglioni, C
    Maestro, R
    Vukosavljevic, T
    Gasparotto, D
    DOrazi, C
    Boiocchi, M
    INTERNATIONAL JOURNAL OF CANCER, 1997, 74 (01) : 26 - 30
  • [23] Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
    Yu, Jiayi
    Yan, Junya
    Guo, Qian
    Chi, Zhihong
    Tang, Bixia
    Zheng, Bin
    Yu, Jinyu
    Yin, Ting
    Cheng, Zhiyuan
    Wu, Xiaowen
    Yu, Huan
    Dai, Jie
    Sheng, Xinan
    Si, Lu
    Cui, Chuanliang
    Bai, Xue
    Mao, Lili
    Lian, Bin
    Wang, Xuan
    Yan, Xieqia
    Li, Siming
    Zhou, Li
    Flaherty, Keith T.
    Guo, Jun
    Kong, Yan
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6511 - 6523
  • [24] Enhancing drug delivery with supramolecular amphiphilic macrocycle nanoparticles: selective targeting of CDK4/6 inhibitor palbociclib to melanoma
    Attia, Mohamed F.
    Ogunnaike, Edikan A.
    Pitz, Megan
    Elbaz, Nancy M.
    Panda, Dillip K.
    Alexander-Bryant, Angela
    Saha, Sourav
    Whitehead, Daniel C.
    Kabanov, Alexander
    BIOMATERIALS SCIENCE, 2024, 12 (03) : 725 - 737
  • [25] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Lu, Janice
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [26] Palbociclib: a first-in-class CDK4/CDK6 inhibitor for the treatment of hormone-receptor positive advanced breast cancer
    Janice Lu
    Journal of Hematology & Oncology, 8
  • [27] The CDK4/6 inhibitor palbociclib enhances the vulnerability of Merkel cell carcinoma via the HIF2α pathway
    Lee, J.
    Colunga, A.
    Lee, J.
    Pulliam, T.
    Paulson, K.
    Voillet, V.
    Berndt, A.
    Church, C.
    Lachance, K.
    Park, S.
    Yamamoto, N.
    Cook, M.
    Kawasumi, M.
    Nghiem, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S122 - S122
  • [28] Palbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast Cancer
    Ettl, Johannes
    BREAST CARE, 2016, 11 (03) : 174 - 176
  • [29] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)
    Galardi, F.
    Biagioni, C.
    De Luca, F.
    Curigliano, G.
    Minisini, A. M.
    Bonechi, M.
    Moretti, E.
    Risi, E.
    Migliaccio, I.
    McCartney, A.
    Benelli, M.
    Romagnoli, D.
    Conti, V.
    Biganzoli, L.
    Di Leo, A.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S18 - S18
  • [30] P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib
    Mark C. de Gooijer
    Ping Zhang
    Nishita Thota
    Isabel Mayayo-Peralta
    Levi C. M. Buil
    Jos H. Beijnen
    Olaf van Tellingen
    Investigational New Drugs, 2015, 33 : 1012 - 1019
12345